Enhanced Insulin Management System

An advanced insulin management system that utilizes patient condition parameters and sequential glucose measurements to provide personalized insulin dosing, real-time alerts, and optimized glycemic management.

The original patent for insulin management has limitations in terms of manually calculating insulin doses, relying on EMR systems, and lacking personalized insulin sensitivity factors. This new inventive concept addresses these limitations by introducing a more efficient, accurate, and patient-centric approach to insulin administration.

The enhanced insulin management system consists of a glucose monitoring module, dose calculation module, and alert generation module. The system receives sequential glucose measurements and patient condition parameters to determine a personalized dose of insulin based on a target blood glucose range. The dose calculation module analyzes the parameters and measurements to determine a patient-specific insulin sensitivity factor, ensuring accurate dosing. The alert generation module generates real-time alerts when the patient's blood glucose level deviates from the target range by a predetermined amount. Additionally, the system provides a clinical decision support system for glycemic management, tracking patient status, and adjusting insulin doses based on the rate of change of the patient's blood glucose level.

The new claims introduce a novel approach to insulin management by incorporating patient condition parameters, sequential glucose measurements, and personalized insulin sensitivity factors. The inventive step lies in the system's ability to provide accurate, real-time, and patient-centric insulin dosing, which is not addressed by the original patent.

Alternative embodiments of the inventive concept could include integrating the system with wearable devices, mobile applications, or artificial intelligence platforms to enhance patient engagement and data analysis. Variations could also include adapting the system for use in different clinical settings, such as outpatient care or pediatric care.

The enhanced insulin management system has significant commercial potential in the healthcare industry, particularly in the areas of diabetes management, glycemic control, and patient safety. The system could be marketed to hospitals, clinics, and healthcare providers, offering a competitive advantage in terms of improved patient outcomes, reduced healthcare costs, and enhanced patient satisfaction.